Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/222767
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition |
Autor: | Quijada-Álamo, Miguel; Hernández-Sánchez, María; Alonso-Pérez, Verónica CSIC ORCID; Rodríguez-Vicente, Ana Eugenia; García-Tuñón, Ignacio CSIC ORCID CVN; Martín-Izquierdo, Marta; Hernandez-Sánchez, Jesus M.; Herrero, Ana B. CSIC ORCID; Bastida, José María; San-Segundo, Laura CSIC; Gruber, Michaela; García, Juan L. CSIC ORCID CVN ; Yin, Shanye; Hacken, Elisa ten; Benito, Rocío; Ordóñez, José Luis CSIC ORCID CVN; Wu, Catherine J.; Hernández, Jesús M. CSIC ORCID | Fecha de publicación: | 2020 | Editor: | Springer Nature | Citación: | Leukemia 34: 1599-1612 (2020) | Resumen: | The deletion of 11q (del(11q)) invariably comprises ATM gene in chronic lymphocytic leukemia (CLL). Concomitant mutations in this gene in the remaining allele have been identified in 1/3 of CLL cases harboring del(11q), being the biallelic loss of ATM associated with adverse prognosis. Although the introduction of targeted BCR inhibition has significantly favored the outcomes of del(11q) patients, responses of patients harboring ATM functional loss through biallelic inactivation are unexplored, and the development of resistances to targeted therapies have been increasingly reported, urging the need to explore novel therapeutic approaches. Here, we generated isogenic CLL cell lines harboring del(11q) and ATM mutations through CRISPR/Cas9-based gene-editing. With these models, we uncovered a novel therapeutic vulnerability of del(11q)/ATM-mutated cells to dual BCR and PARP inhibition. Ex vivo studies in the presence of stromal stimulation on 38 CLL primary samples confirmed a synergistic action of the combination of olaparib and ibrutinib in del(11q)/ATM-mutated CLL patients. In addition, we showed that ibrutinib produced a homologous recombination repair impairment through RAD51 dysregulation, finding a synergistic link of both drugs in the DNA damage repair pathway. Our data provide a preclinical rationale for the use of this combination in CLL patients with this high-risk cytogenetic abnormality. | Versión del editor: | https://doi.org/10.1038/s41375-020-0714-3 | URI: | http://hdl.handle.net/10261/222767 | DOI: | 10.1038/s41375-020-0714-3 | ISSN: | 0887-6924 | E-ISSN: | 1476-5551 |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
crisinhibi.pdf | 3,57 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
16
checked on 30-mar-2024
SCOPUSTM
Citations
19
checked on 18-abr-2024
WEB OF SCIENCETM
Citations
18
checked on 27-feb-2024
Page view(s)
148
checked on 19-abr-2024
Download(s)
131
checked on 19-abr-2024